Researchers at Dana-Farber Cancer Institute collaborated with multiple institutions to pinpoint rare germline structural ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision T cell activation, today announced that Zhen Su, M.D., MBA, the Company's Chief Executive ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Dana-Farber Cancer Institute research shows inherited genetic variants increase risk of certain paediatric cancers: Boston, Massachusetts Monday, January 6, 2025, 10:00 Hrs [IST] ...

I recently watched an episode of one of my favourite TV shows, the Good Doctor. The episode revolved around how a man named Wyatt was rushed into the ER as he had a perforated valve and needed ...

Researchers have developed an AI model that accurately predicts gene activity in any human cell, providing insights into ...

The pair had helped identify a still-unnamed disease, which they had tied to a particular gene and to a particular somatic ...

A germ-line mutation looks like a red ball in a ... their potential causes was Erdheim-Chester disease, a rare blood-cell disorder that arises due to somatic mutations. I wondered whether I ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...